{
    "Project Title": "NIS-PSO-TARGET Non-Interventional Study Protocol",
    "Sponsor": "LEO pharma France",
    "Study Number": "RCB: 2020-A00652-37",
    "Protocol Version and Date": "Not Available",
    "Study Title": "NIS-PSO-TARGET Non-Interventional Study Protocol",
    "Phase": "Not Available",
    "Therapeutic Area": "Psoriasis",
    "Number of Patients": "150",
    "Number of Sites": "Not Available",
    "Indication": "Psoriasis",
    "Duration of Treatment": "52 \u00b1 4 weeks",
    "Schedule of Assessments": "Table 1 (Study Schedule)",
    "questionnaires": [
        {
            "longName": "Psoriasis Area and Severity Index",
            "shortName": "PASI",
            "type": "ClinRO",
            "questionnaireSchedule": "Baseline, 1st follow-up at 12/16 weeks, 2nd follow-up at 52 \u00b1 4 weeks",
            "questionnaireTiming": [
                "Reporter: Base-line Visit (Day 0)",
                "Reporter: 3 months Visit (week 12-16)",
                "Reporter: 12 months visit (week 48-56)"
            ]
        },
        {
            "longName": "Dermatology Life Quality Index",
            "shortName": "DLQI",
            "type": "PRO",
            "questionnaireSchedule": "Baseline, 1st follow-up at 12/16 weeks, 2nd follow-up at 52 \u00b1 4 weeks",
            "questionnaireTiming": [
                "Reporter: Base-line Visit (Day 0)",
                "Reporter: 3 months Visit (week 12-16)",
                "Reporter: 12 months visit (week 48-56)"
            ]
        },
        {
            "longName": "PSO-TARGET QoL Component grid",
            "shortName": "PSO-TARGET grid",
            "type": "PRO",
            "questionnaireSchedule": "Administered at baseline and at 1st follow-up at 12/16 weeks",
            "questionnaireTiming": [
                "Reporter: Base-line Visit (Day 0)",
                "Reporter: 3 months Visit (week 12-16)",
                "Reporter: 12 months visit (week 48-56)"
            ]
        }
    ]
}